• De-Tao Yin, Kun Yu, Run-Qing Lu, Xianghua Li, Jianhui Xu, and Mengyuan Lei.
• Department of Thyroid Surgery, the First Affiliated Hospital of Zhengzhou University Key Discipline Laboratory of Clinical Medicine Henan Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
• Medicine (Baltimore). 2016 Dec 1; 95 (52): e5794e5794.

BackgroundIt is widely accepted that maximal extrathyroidal extension (ETE) plays a vital role in the prognosis of papillary thyroid carcinoma (PTC). However, there is no consensus among researchers about the meaning of minimal ETE (mETE) in PTC. Herein, we conducted a systematic review and meta-analysis to examine the role of mETE in the prognosis of PTC.MethodsWe searched PubMed, EMBASE, and Cochrane search trials databases in English to identify studies comparing data on disease recurrence in PTC patients with mETE and those with no ETE. To summarize the data related to mETE status, risk ratios and hazard ratios adjusted for potential confounders were used to assess the number of recurrence and time-dependent risks related to mETE status, respectively.ResultsAccording to the inclusion criteria, a total of 7951 patients from 9 studies were included. The recurrence rate in patients with mETE is significantly higher when compared with those with no ETE (risk ratio = 1.70, 95% confidence interval: 1.26-2.28, I = 56%). According to the data summarized with hazard ratios, PTC patients with mETE showed a significantly increased risk of disease recurrence.ConclusionmETE is a risk factor for poor prognosis in patients with PTC. Our innovative classification of ETE has its value in assessing the prognosis of PTC.

14 keywords...

hide…